Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

atters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX2931 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty ... for the second quarter ended June 30, 2014. ... $6.5 million in the second quarter of 2014, an increase ... Total revenues of $13.3 million for the six months ended ... period in 2013 , Total revenues generated from the ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... BUFFALO, N.Y. , July 24, 2014  Kinex ... US FDA for the Company,s KX2-391 Ointment for the ... keratosis. This is the Company,s third IND to be ... months. KX2-391 is a synthetic, orally active ... and tubulin polymerization. KX2-391 promotes the induction of p53, ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... Asthmatx, Inc. presented the results of a series ... thermoplasty delivered by the Alair® System, and how this ... in a poster at the 2009 Annual Meeting of ... in Miami Beach, Fla. , The poster, titled "Where ...
... PALO ALTO, Calif., Nov. 9 Women,s sexual health company, ... as it prepares for a 2010 launch of its Viveve ... a name that we believe captures the essence of our ... president and chief executive. "Viveve exists for the sole purpose ...
Cached Medicine Technology:Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting 2Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting 3Women's Sexual Health Company Changes Name in Preparation for Market Entry 2
(Date:7/24/2014)... York (PRWEB) July 24, 2014 ... ( http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District ... protective order for plaintiff medical information covered by ... According to the July 16th Order, U.S. District ... for Fresenius Medical Care the right to ...
(Date:7/24/2014)... Amy Norton HealthDay Reporter ... of the sex-crazed teenage boy may be dead wrong, according to ... romantic relationships. In interviews with 33 boys between the ages ... a relationship with a girl for the closeness and trust. Very ... goal" in starting a relationship with a girl. "In our ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July ... don,t view their kids as unhealthy or recognize the health ... study. The children of the families surveyed for the ... Children,s Hospital in Providence, R.I. "A third categorized their ... Dr. Kyung Rhee, now an assistant professor of pediatrics at ...
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
(Date:7/24/2014)... News Facts , Lexmark’s ... certification for compliance with Department of Defense (DoD) ... DoD Information Assurance Certification and Accreditation Process (DIACAP). ... the DoD as the Enterprise Clinical Imaging Archive, ... the U.S. Army Medical Materiel Agency. , DIACAP ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4
... Gives Washington Residents Access to Nursing Home, Assisted ... Nearly Every Zip Code Statewide RICHMOND, Va., April 30 ... in Washington is rising at a rate outpacing inflation, putting ... to an annual study by Genworth Financial. At the ...
... Utah Residents Access to Nursing Home, Assisted Living, Home Care ... Code StatewideRICHMOND, Va., April 30 The cost ... rate outpacing inflation, putting significant financial pressure on those in ... Financial. At the same time, the current economic downturn ...
... Assisted Living, Home Care and Adult Day Health Care Costs ... The cost of long term care in Rhode ... financial pressure on those in or near retirement, according to ... time, the current economic downturn has led to a decline ...
... middle-age and beyond, study suggests , , WEDNESDAY, April 29 (HealthDay ... much earlier in life than it currently does, say Canadian ... , The study of 400 women, ages 15 to ... young women may be associated with their risk for breast ...
... production system are biggest challenges, experts say , , THURSDAY, April ... swine flu pandemic, U.S. health officials are already collecting information ... vaccine. , And even though experts say there,s no guarantee ... -- would work, many agree it,s the logical next step. ...
... half of those surveyed believe agency is falling behind ... News) -- Although the American public feels a little ... Administration is doing now than a year ago, about ... safeguard the country,s food and drugs, a new Harris ...
Cached Medicine News:Health News:Growth in Washington Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Washington Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Washington Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in Utah Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Utah Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Utah Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in Rhode Island Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Rhode Island Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Rhode Island Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Young Women's Breast Tissue Offers Clues to Cancer Risk 2Health News:Swine Flu Vaccine Still Months Away 2Health News:Swine Flu Vaccine Still Months Away 3Health News:U.S. Public Lacks Confidence in FDA: Poll 2Health News:U.S. Public Lacks Confidence in FDA: Poll 3Health News:U.S. Public Lacks Confidence in FDA: Poll 4
... airways., ,When a difficult airway must ... Now you can be assured of rapid ... Esophageal/Tracheal double-Lumen Airway from Nellcor. Unlike traditional ... to establish a nonsurgical patient airway when ...
Guedel-style enclosed center channel. Semirigid, nontoxic polyethylene with color-coded bite block. Individually packaged, 48 per case. Latex Free....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile and individually bagged....
Medicine Products: